Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

被引:48
|
作者
Bedard, Philippe L. [1 ]
de Azambuja, Evandro [1 ]
Cardoso, Fatima [1 ]
机构
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
关键词
Breast neoplasms; erbB-2; receptor; monoclonal antibodies; protein-tyrosine kinases; ACTIVATED PROTEIN-KINASE; PHASE-II TRIAL; C-MYC AMPLIFICATION; TYROSINE KINASE; MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; ANTI-ERBB2; ANTIBODIES; EXTRACELLULAR DOMAIN; CELL-PROLIFERATION;
D O I
10.2174/156800909787581024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of the human epidermal growth factor receptor 2 (HER-2) represents a biological subclass of breast cancer with distinct molecular alterations, clinical behavior, and response to systemic therapy. Trastuzumab is a monoclonal antibody directed against HER-2 which has revolutionized the management of both early and advanced breast cancer. It may exert its anti-cancer effects through inhibition of intracellular signaling, upregulation of p27, impaired angiogenesis, induction of immune-mediated destruction, and blockade of cleavage of the extracellular domain of HER-2. In spite of its robust clinical activity, most women with metastatic HER-2 overexpressing breast cancer eventually progress on trastuzumab therapy. Possible mechanisms of resistance include: altered receptor antibody interaction, PTEN loss and enhanced Akt signaling, p27 loss, signaling through other receptors. Preclinical experiments, clinical experience with the use of trastuzumab beyond progression, and a recent phase III clinical trial with Lapatinib, a dual EGFR/HER-2 tyrosine kinase inhibitor, demonstrate that the HER-2 signaling axis remains an important therapeutic target even after progression on trastuzumab. A variety of novel strategies are currently in development to exploit this pathway following the onset of resistance, such as receptor antibodies, sheddase inhibitors, signal transduction inhibitors, heat shock protein inhibitors, proteasome inhibitors, anti-angiogenic agents, and immune-stimulatory therapies, either as single agents or in combination with trastuzumab. Rational clinical trial design, with attention to appropriate patient selection and prospective collection of biological material, is needed to ensure that the new generation of anti-HER-2 targeted therapies realizes its promise in the treatment of trastuzumab-resistant disease.
引用
收藏
页码:148 / 162
页数:15
相关论文
共 50 条
  • [31] Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab
    Jiang, Shuai
    Geng, Shuai
    Gao, Xinyue
    Liu, Tong
    Luo, Xinyu
    Wang, Nan
    Shi, Ning
    Dong, Mei
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2023, 45 (05) : 616 - 625
  • [32] Targeted inhibition of HER-2 positive breast cancer cells by trastuzumab functionalized pullulan-doxorubicin nanoparticles
    Xu, Ruiling
    Sui, Junhui
    Zhao, Mingda
    Yang, Yuedi
    Tong, Lei
    Liu, Yongmei
    Sun, Yong
    Fan, Yujiang
    Liang, Jie
    Zhang, Xingdong
    POLYMER TESTING, 2022, 113
  • [33] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Juin Park
    Sun Kyoung Kang
    Woo Sun Kwon
    Inhye Jeong
    Tae Soo Kim
    Seo Young Yu
    Sang Woo Cho
    Hyun Cheol Chung
    Sun Young Rha
    Scientific Reports, 13
  • [34] Targeted inhibition of HER-2 positive breast cancer cells by trastuzumab functionalized pullulan-doxorubicin nanoparticles
    Xu, Ruiling
    Sui, Junhui
    Zhao, Mingda
    Yang, Yuedi
    Tong, Lei
    Liu, Yongmei
    Sun, Yong
    Fan, Yujiang
    Liang, Jie
    Zhang, Xingdong
    Polymer Testing, 2022, 113
  • [35] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Park, Juin
    Kang, Sun Kyoung
    Kwon, Woo Sun
    Jeong, Inhye
    Kim, Tae Soo
    Yu, Seo Young
    Cho, Sang Woo
    Chung, Hyun Cheol
    Rha, Sun Young
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [36] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Dieras, Veronique
    Bachelot, Thomas
    TARGETED ONCOLOGY, 2014, 9 (02) : 111 - 122
  • [37] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Véronique Diéras
    Thomas Bachelot
    Targeted Oncology, 2014, 9 : 111 - 122
  • [38] Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer
    Masafumi Kurosumi
    Breast Cancer, 2009, 16 : 283 - 283
  • [39] Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy
    Otchere, Prince
    Adekoya, Olusola
    Governor, Samuel B. B.
    Vuppuluri, Naveen
    Prabhakar, Akruti
    Pak, Stella
    Oppong-Nkrumah, Oduro
    Cook, Francis
    Bohinc, Rudy
    Aune, Gregory
    CARDIO-ONCOLOGY, 2023, 9 (01)
  • [40] Safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer.
    Griggs, JJ
    Schiffhauer, LM
    Sahasrabudhe, DM
    Pandya, KJ
    Caldwell, C
    Peacock, J
    Messina, P
    Spreng, E
    Bourne, P
    McGuire, GM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 76S - 76S